Antireflux Surgery for Barrett's Esophagus: Where Do We Stand in Preventing Esophageal Adenocarcinoma?
Annals of the New York Academy of Sciences · 2026
DOI: 10.1111/nyas.70196 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Annals of the New York Academy of Sciences, 2026. Verfasst von Dagmar Kollmann und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of General Surgery, Medical University of Vienna, Vienna, Austria. Hauptthemen laut MEDLINE: Barrett Esophagus, Adenocarcinoma, Esophageal Neoplasms, Gastroesophageal Reflux. Die Arbeit nennt 84 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Esophageal adenocarcinoma is a major global health concern, primarily arising from gastroesophageal reflux disease, with Barrett's esophagus being its main precursor. Although proton pump inhibitors are commonly used to manage the symptoms from gastroesophageal reflux disease, their role in preventing esophageal adenocarcinoma progression remains uncertain. The aim of this review is to summarize the current advances in the diagnosis of Barrett's esophagus and its progression, as well as to critically evaluate and compare the impact of antireflux surgery on Barrett's esophagus and its potential role in preventing its progression to esophageal adenocarcinoma. In conclusion, surgical intervention, particularly antireflux surgery, has been associated with reduced esophageal adenocarcinoma risk in some studies, offering better long‐term symptom control and possibly preventing cancer progression. However, other authors suggest that the cancer risk does not decrease significantly with surgery, highlighting the need for further investigation into its long‐term preventive benefits. Several novel strategies have been established over the last few years that will facilitate an early diagnosis of Barrett's esophagus in the future.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of General Surgery, Medical University of Vienna, Vienna, Austria.
- UT MD Anderson Cancer Center, Houston, Texas, USA.
- Gastroenterology and Hepatology, Augusta University Medical College of Georgia, Augusta, Georgia, USA.
- Sao Leopoldo Mandic School of Medicine, Campinas, Brazil.
- Division of Gastroenterology and Hepatology, Department of Medicine, Stanford University School of Medicine, Redwood City, California, USA.
- Department of Pathology, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA.
Zitieren
APA
Kollmann, D., Etyemez, C., Asari, R., Jomrich, G., Triadafilopoulos, G., Vega, K. J., Zilberstein, B., Zhou, M. J., Huang, Q., Mashimo, H., Shin, E. J., Clark, J. O., & Schoppmann, S. F. (2026). Antireflux Surgery for Barrett's Esophagus: Where Do We Stand in Preventing Esophageal Adenocarcinoma?. Annals of the New York Academy of Sciences. https://doi.org/10.1111/nyas.70196
Vancouver
Kollmann D, Etyemez C, Asari R, Jomrich G, Triadafilopoulos G, Vega KJ, et al. Antireflux Surgery for Barrett's Esophagus: Where Do We Stand in Preventing Esophageal Adenocarcinoma?. Annals of the New York Academy of Sciences. 2026. doi:10.1111/nyas.70196
BibTeX
@article{Kollmann2026,
author = {Kollmann, Dagmar and Etyemez, Cansel and Asari, Reza and Jomrich, Gerd and Triadafilopoulos, George and Vega, Kenneth J and Zilberstein, Bruno and Zhou, Margaret J and Huang, Qin and Mashimo, Hiroshi and Shin, Eun Ji and Clark, John O and Schoppmann, Sebastian F},
title = {Antireflux Surgery for Barrett's Esophagus: Where Do We Stand in Preventing Esophageal Adenocarcinoma?},
journal = {Annals of the New York Academy of Sciences},
year = {2026},
doi = {10.1111/nyas.70196}
}
EUVIMED